Research Paper Mediators of Inflammation, 10, 21–26 (2001)

BACKGROUND: In smoking COPD patients the bronchoalveolar lavage (BAL) fluid contains high numbers of inflammatory cells. These cells might produce arachidonic acid (AA) metabolites, which contribute to inflammation and an increased bronchomotor tone. AIMS: To investigate levels of AA metabolites in BAL fluid, before and after inhaled glucocorticoid therapy: fluticasone propionate (FP) 1 mg per day, or placebo. METHODS: A double-blind placebo controlled trial lasting six months. COPD patients were selected by clinical criteria and the presence of bronchial hyper-responsiveness (BHR). Lung function was recorded and in BAL fluid we counted cell numbers and measured LTB4, LTC4/D4/E4, PGE2, 6kPGF1alpha, PGF2alpha and TxB2. A control group consisted of asymptomatic smokers (n=6). RESULTS: Paired data were obtained from 9 FP treated and 11 placebo patients. BAL cells were almost exclusively alveolar macrophages. In patients and controls both cellularity and levels of AA metabolites were equal Cell numbers did not change after treatment. Statistically significant decreases after FP therapy were noticed for PGE2 (30%), 6kPGF1alpha (41%) and PGF2alpha (54%). CONCLUSIONS: In COPD, the capability of inflammatory cells to produce certain AA metabolites was decreased after inhaled FP treatment. This result is discussed in its relation to clinical effects, the influence of smoking, and the results of an earlier, similar study in asthma patients.

[1]  B. Rosner,et al.  Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. , 1995, American journal of respiratory and critical care medicine.

[2]  B. Make,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[3]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[4]  S. Holgate,et al.  Cholinergic-Mediated Bronchoconstriction Induced by Prostaglandin D2, Its Initial Metabolite 9α, 11β-PGF2, and PGF2α in Asthma , 1987 .

[5]  J. Connett,et al.  Methacholine reactivity predicts changes in lung function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research Group. , 1996, American journal of respiratory and critical care medicine.

[6]  Summary and recommendations of a workshop on the investigative use of fiberoptic bronchoscopy and bronchoalveolar lavage in asthmatics. , 1985, The American review of respiratory disease.

[7]  H. Hoogsteden,et al.  Eicosanoid levels in bronchoalveolar lavage fluid of young female smokers and non‐smokers , 1992, European journal of clinical investigation.

[8]  M. Richter,et al.  Effects of eicosanoids, neuromediators and bioactive peptides on murine airways. , 2000, European journal of pharmacology.

[9]  H. Hoogsteden,et al.  Lower leukotriene C4 levels in bronchoalveolar lavage fluid of asthmatic subjects after 2.5 years of inhaled corticosteroid therapy , 1995, Mediators of inflammation.

[10]  H. Hoogsteden,et al.  Effects of fluticasone propionate on arachidonic acid metabolites in BAL-fluid and methacholine dose-response curves in non-smoking atopic asthmatics , 1996, Mediators of inflammation.

[11]  L. Y. Lee,et al.  Involvement of prostanoids in cigarette smoking-induced pathophysiological effects in the lung. , 1999, Prostaglandins, leukotrienes, and essential fatty acids.

[12]  P. Jeffery,et al.  Comparison of the structural and inflammatory features of COPD and asthma. Giles F. Filley Lecture. , 2000, Chest.

[13]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.